In last trading session, Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) saw 0.74 million shares changing hands with its beta currently measuring 1.53. Company’s recent per share price level of $16.63 trading at -$0.12 or -0.72% at ring of the bell on the day assigns it a market valuation of $2.19B. That closing price of CNTA’s stock is at a discount of -14.79% from its 52-week high price of $19.09 and is indicating a premium of 53.4% from its 52-week low price of $7.75.
For Centessa Pharmaceuticals plc ADR (CNTA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.35 in the current quarter.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information
Upright in the red during last session for losing -0.72%, in the last five days CNTA remained trading in the red while hitting it’s week-highest on Friday, 02/14/25 when the stock touched $16.63 price level, adding 10.35% to its value on the day. Centessa Pharmaceuticals plc ADR’s shares saw a change of -0.72% in year-to-date performance and have moved -5.62% in past 5-day. Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) showed a performance of -0.30% in past 30-days.
Wall Street analysts have assigned a consensus price target of 23 to the stock, which implies a rise of 27.7% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 28. It follows that stock’s current price would drop -14.25% in reaching the projected high whereas dropping to the targeted low would mean a loss of -14.25% for stock’s current value.
Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts
This year revenue growth is estimated to fall -100.00% from the last financial year’s standing.
In 2025, company’s earnings growth rate is likely to be around 2.97% while estimates for its earnings growth in next 5 years are of -3.20%.
Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD is the top institutional holder at CNTA for having 19.96 million shares of worth $180.27 million. And as of 2024-06-30, it was holding 18.233 of the company’s outstanding shares.
The second largest institutional holder is GENERAL ATLANTIC, L.P., which was holding about 9.68 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8427 of outstanding shares, having a total worth of $87.43 million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) Health Sciences Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.98 shares of worth $49.5 million or 2.26% of the total outstanding shares. The later fund manager was in possession of 2.95 shares on Sep 30, 2024 , making its stake of worth around $49.01 million in the company or a holder of 2.24% of company’s stock.
